Parkinson Disease

How Managed Care Pharmacists Can Improve Current Standards of Treatment for Parkinson Disease

December 1st 2020, 11:06pm


Managed care pharmacists can influence several aspects of care in Parkinson disease, particularly through determining clinical pathways and educating patients and providers on novel agents coming to market.

What Can Alleviate Levodopa-Induced Dyskinesia in Parkinson Disease?

November 27th 2020, 3:00pm


Low-frequency transcranial stimulation of the pre-supplementary motor area was found to delay the onset and reduce severity of levodopa-induced dyskinesia in patients with Parkinson disease.

How an Eye Exam May Improve Early Diagnosis of Parkinson Disease

November 23rd 2020, 8:00pm


An eye exam paired with artificial intelligence machine learning technology may provide a novel approach to diagnose Parkinson disease in early stages.

Dr Patty Taddei-Allen on Therapeutic Advances in Parkinson Disease

November 19th 2020, 10:16pm


In addition to different dosage forms of levodopa—the current standard of care for Parkinson disease—emerging trials are also examining alpha-synuclein, an abnormal protein that may be involved in the pathogenesis of the condition.

Machine Learning Approach May Offer Future Diagnostic Advances in Parkinson Disease

November 16th 2020, 8:00pm


A machine learning approach that works to identify mitochondrial impairments, a potential mechanism underlying the pathogenesis of Parkinson disease (PD), accurately distinguished between patients with PD and healthy controls.

How Tremor Affects Learning Abilities in Patients With Parkinson Disease

November 13th 2020, 8:12pm


Patients with Parkinson disease (PD) who do not experience tremor were found to show improvements in reward learning after taking dopaminergic medication, while those with PD and tremor exhibited no benefit in reinforcement learning.

A Patient Perspective on Misconceptions, Challenges in Parkinson Disease

November 11th 2020, 10:29pm


Michael S. Fitts, assistant dean for user access and diversity at the University of Alabama at Birmingham, discusses misconceptions of Parkinson disease related to race and age, as well as advice for patients in their treatment journey.

How Socioeconomic Status Influences Mortality Risk in Patients With Parkinson Disease

November 6th 2020, 7:13pm


Individual-level low socioeconomic status (SES) was found to be significantly associated with increased mortality in Korean patients with Parkinson disease, whereas regional-level SES was not.

A Review of Stem Cell–Based Therapies for Parkinson Disease

November 3rd 2020, 7:00pm


Researchers discuss the development and potential of stem cell–based therapies in the treatment of Parkinson disease.

A Patient Perspective on the Progressive Nature of PD, Impact of Nonmotor Symptoms

October 29th 2020, 9:32pm


Michael S. Fitts, assistant dean for user access and diversity for The University of Alabama at Birmingham, discusses reporting on the progressive symptoms of Parkinson disease, and the impact of nonmotor symptoms of anxiety and depression.